The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

A novel drug almost entirely cleared moderate to severe psoriasis in over 60% of the patients who took part in two phase three clinical trials of a new drug. The University of Manchester and Salford ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

Johnson & Johnson has won US approval for its new psoriasis drug, taking on the likes of Novartis, Eli Lilly and Valeant in an increasingly crowded market. The FDA has backed guselkumab ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

The company, based in Nijmegen, is developing both oral and topical RORγt drug candidates for psoriasis and other autoimmune diseases. The market for new psoriasis and related immunology ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...